MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.50−0.37 (-2.87%)
Close on Nov 13, 2026Market cap $1.06BP/E –Yield –
MoonLake Immunotherapeutics total assets
Total assets on the balance sheet at the end of each period.
MoonLake Immunotherapeutics's total assets was $540.72M at Sep 30, 2026. For fiscal 2025 it was $424.43M, down 11.2% from the year before. The highest annual figure on record is $526.54M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $424.43M | -11.2% |
| FY2024 | Dec 31, 2024 | $477.93M | -9.2% |
| FY2023 | Dec 31, 2023 | $526.54M | +585.2% |
| FY2022 | Dec 31, 2022 | $76.84M | +693.6% |
| FY2021 | Dec 31, 2021 | $9.68M | -91.7% |
| FY2020 | Dec 31, 2020 | $116.63M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $540.72M | +30.5% |
| Q2 FY2026 | Jun 30, 2026 | $573.95M | +24.7% |
| Q1 FY2026 | Mar 31, 2026 | $400.37M | -21.7% |
| Q4 FY2025 | Dec 31, 2025 | $424.43M | -11.2% |
| Q3 FY2025 | Sep 30, 2025 | $414.34M | -20.0% |
| Q2 FY2025 | Jun 30, 2025 | $460.10M | -15.6% |
| Q1 FY2025 | Mar 31, 2025 | $511.26M | -9.4% |
| Q4 FY2024 | Dec 31, 2024 | $477.93M | -9.2% |
| Q3 FY2024 | Sep 30, 2024 | $518.21M | +3.6% |
| Q2 FY2024 | Jun 30, 2024 | $544.88M | +7.6% |
| Q1 FY2024 | Mar 31, 2024 | $564.12M | +744.5% |
| Q4 FY2023 | Dec 31, 2023 | $526.54M | +585.2% |
| Q3 FY2023 | Sep 30, 2023 | $500.22M | +464.6% |
| Q2 FY2023 | Jun 30, 2023 | $506.62M | +414.7% |
| Q1 FY2023 | Mar 31, 2023 | $66.80M | -71.1% |
| Q4 FY2022 | Dec 31, 2022 | $76.84M | +693.6% |
| Q3 FY2022 | Sep 30, 2022 | $88.59M | -23.8% |
| Q2 FY2022 | Jun 30, 2022 | $98.43M | -15.4% |
| Q1 FY2022 | Mar 31, 2022 | $231.21M | +98.5% |
| Q4 FY2021 | Dec 31, 2021 | $9.68M | -91.7% |
| Q3 FY2021 | Sep 30, 2021 | $116.25M | +70993.5% |
| Q2 FY2021 | Jun 30, 2021 | $116.37M | – |
| Q1 FY2021 | Mar 31, 2021 | $116.49M | – |
| Q4 FY2020 | Dec 31, 2020 | $116.63M | – |
| Q3 FY2020 | Sep 30, 2020 | $163.51K | – |
See a number that looks wrong?